Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Endocyte receives payment for the advancement of epothilone-folate anti-cancer agent

Endocyte, Inc., a cancer drug discovery and development company, today announced it has received a milestone payment from Bristol-Myers Squibb Company (NYSE: BMY). This payment was triggered by the commencement of a Phase II clinical trial for an epothilone-folate anti-cancer agent identified through the collaboration between Endocyte and Bristol-Myers Squibb scientists.

26 Aug 2009

OriGene Technologies releases recombinant proteins purified from HEK293 cells

OriGene Technologies, Inc. announces the release of 5,000 purified human proteins, representing the most comprehensive offering of human cell-produced human proteins.

25 Aug 2009

Karo Bio collaborates with Wyeth for treating inflammatory diseases

The Swedish biotech company Karo Bio today announced that beginning September 1, 2009, Wyeth will take on all future research and development activities under the drug discovery collaboration between the parties.

25 Aug 2009

Nutra Pharma submits final packaging and labeling for Cobroxin drug for FDA approval

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully submitted final packaging and labeling to the Food and Drug Administration (FDA) to begin selling Cobroxin, an over-the-counter (OTC) treatment for stage 2 (moderate to severe) chronic pain.

25 Aug 2009

Lpath achieves one of the four Phase 1 objectives by demonstrating its optimized fermentation process

Lpath, Inc., the category leader in lipidomics-based therapeutics, demonstrated commercially acceptable yields in its optimized fermentation process. In doing so, Lpath achieved one of four Phase 1 objectives established by Merck Serono, the exclusive worldwide licensee of ASONEP and Lpath's development partner, and will receive a milestone payment according to the terms of the Merck Serono license agreement.

25 Aug 2009

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Neurogen Corporation (NASDAQ:NRGN) announced today they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock and will be granted Contingent Value Rights (“CVRs”) under four CVR agreements.

25 Aug 2009

Santaris Pharma to discover and develop new RNA-based medicines for treating rare genetic disorders

Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced a multi-year worldwide strategic alliance with Shire plc to discover and develop new RNA-based medicines to treat rare genetic disorders.

24 Aug 2009

Sigma-Aldrich scientists to leverage proprietary gene editing technology to develop genetically-engineered rodent research models

Sigma-Aldrich(R) (Nasdaq: SIAL) announced today that scientists at its new Sigma Advanced Genetic Engineering (SAGE(TM)) Labs in St. Louis will leverage its exclusive CompoZr(TM) Zinc Finger Nuclease (ZFN) gene editing technology (www.compozrzfn.com) to define, develop and offer a new generation of genetically-engineered rodent research models. Such models are commonly used to study disease states in humans and play a key role in the drug discovery process.

24 Aug 2009

Ron Demuth of ChemDiv announces extension of collaboration with Lilly

ChemDiv, Inc. announced the expansion of its drug discovery collaboration with Eli Lilly through 2010. Under the terms of the agreement, the partners will identify and develop leads for an additional therapeutic target using ChemDiv's small molecule resources (the industry's largest commercial collection) and Discovery outSource™ drug discovery and development platforms.

21 Aug 2009

Nutra Pharma launches Cobroxin for chronic pain relief

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has launched an over-the-counter (OTC) pain reliever, Cobroxin, for the treatment of Stage 2 (moderate to severe) chronic pain.

21 Aug 2009

Southern Research's Birmingham campus to have a Comprehensive Chemical Biology Center

Southern Research Institute today announced that it has been selected as one of 11 organizations to help establish the National Cancer Institute's (NCI) Chemical Biology Consortium (CBC)--a program meant to coordinate and accelerate the discovery and development of new therapeutic agents to treat cancer patients. Southern Research will establish one of NCI's five Comprehensive Chemical Biology Centers at its Birmingham campus.

21 Aug 2009

New antimalarial drug discovery project funded by European Commission

The European Commission is funding a two year, -500,000 project to co-ordinate European and international research into the development of new drugs to treat malaria.

21 Aug 2009

Shape-changing in proteins opens new avenue for drug discovery

Computational biologists at the University of Pittsburgh School of Medicine have shown that proteins have an intrinsic ability to change shape, and this is required for their biological activity. This shape-changing also allows the small molecules that are attracted to a given protein to select the structure that permits the best binding. That premise could help in drug discovery and in designing compounds that will have the most impact on protein function to better treat a host of diseases.

20 Aug 2009

Fluxion Biosciences receives a $1.8 million NIH grant for developing microfluidic platform

Fluxion Biosciences, a leading developer of microfluidic systems for functional cell analysis, today announced that it has received a $1.8 million NIH grant for the development of a high-throughput screening platform for anti-microbial drug discovery.

From Fluxion Biosciences 20 Aug 2009

USPTO grants MultiCell Technologies patent for its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines

MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) announced today it has been granted U.S. patent 7,566,567 by the United States of America Patent and Trademark Office covering its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines.

20 Aug 2009

Vanderbilt enters Chemical Biology Consortium as a Chemical Diversity Center to develop cancer treatment drugs

Vanderbilt University has been selected as one of 10 centers in the nation to participate in the Chemical Biology Consortium (CBC), a major new initiative to facilitate the discovery and development of new agents to treat cancer.

20 Aug 2009

Young innovators Andrea Armani and Ellis Meng to feature in Technology Review magazine's 2009 TR35 list

The University of Southern California today announced that two faculty members from the USC Viterbi School of Engineering have been recognized by Technology Review magazine as some of the world's top innovators under the age of 35. Andrea Armani, Assistant Professor of Chemical Engineering and Materials Science, and Ellis Meng, Assistant Professor of Biomedical Engineering, will both appear on the prestigious 2009 TR35 list.

19 Aug 2009

Xceleron to acquire an Accelerator Mass Spectrometry instrument under agreement with GlaxoSmithKline

XCELERON, a leader in the field of ultra-sensitive bioanalytical studies supporting clinical research, today announced that it has signed a second Master Service Agreement with GlaxoSmithKline. Under the terms of this agreement, Xceleron will provide analytical support to GlaxoSmithKline and its affiliated research organizations. As part of the deal, Xceleron will increase capacity through the acquisition of an Accelerator Mass Spectrometry (AMS) instrument.

19 Aug 2009

Algos Therapeutics changes name to Algos Preclinical Services

Following a shift in its business model from developing proprietary pain therapy products to pure contract research, Algos Therapeutics has changed its name to Algos Preclinical Services. The company's new tagline, "Expertise in pain. Legendary service. Definitive results. For better quality of life." reinforces its repositioning as the go-to-CRO (Contract Research Organization) for drug discovery and product development.

19 Aug 2009

Labcyte awarded 2nd Japanese patent for acoustic-based cell sorting system

Labcyte, the company that developed and commercialized the acoustic transfer of liquids today announced that the Japanese patent office has granted patent 4309131 that covers the design of an acoustic-based system that can sort cells based upon acoustic or other properties and then eject them specifically from a mixed population.

18 Aug 2009

Drug Discovery News and Research

Further Reading

Endocyte receives payment for the advancement of epothilone-folate anti-cancer agent

OriGene Technologies releases recombinant proteins purified from HEK293 cells

Karo Bio collaborates with Wyeth for treating inflammatory diseases

Nutra Pharma submits final packaging and labeling for Cobroxin drug for FDA approval

Lpath achieves one of the four Phase 1 objectives by demonstrating its optimized fermentation process

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Santaris Pharma to discover and develop new RNA-based medicines for treating rare genetic disorders

Sigma-Aldrich scientists to leverage proprietary gene editing technology to develop genetically-engineered rodent research models

Ron Demuth of ChemDiv announces extension of collaboration with Lilly

Nutra Pharma launches Cobroxin for chronic pain relief

Southern Research's Birmingham campus to have a Comprehensive Chemical Biology Center

New antimalarial drug discovery project funded by European Commission

Shape-changing in proteins opens new avenue for drug discovery

Fluxion Biosciences receives a $1.8 million NIH grant for developing microfluidic platform

USPTO grants MultiCell Technologies patent for its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines

Vanderbilt enters Chemical Biology Consortium as a Chemical Diversity Center to develop cancer treatment drugs

Young innovators Andrea Armani and Ellis Meng to feature in Technology Review magazine's 2009 TR35 list

Xceleron to acquire an Accelerator Mass Spectrometry instrument under agreement with GlaxoSmithKline

Algos Therapeutics changes name to Algos Preclinical Services

Labcyte awarded 2nd Japanese patent for acoustic-based cell sorting system

Drug Discovery - Second Edition eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News